PeptideAgentAsk PeptideAgent
Peptide guide · Longevity

SS-31 / Elamipretide: the evidence, status, and research questions.

SS-31 / Elamipretide guide to human and preclinical evidence, research uses, FDA status, sport status, primary sources, and key limits.

Published Evidence reviewed August 7, 20262 inspectable sources7 min read
01What is SS-31 / Elamipretide?02What is the evidence for SS-31 / Elamipretide?03What is SS-31 / Elamipretide being studied for?04Is SS-31 / Elamipretide FDA approved?05Is SS-31 / Elamipretide prohibited in sport?06What are the evidence limits for SS-31 / Elamipretide?

EVIDENCE TAKEAWAY

The short answer.

SS-31 is no longer simply an unapproved research peptide: elamipretide now has one narrow accelerated-approval pathway, with confirmatory evidence still required.

WHAT IS SS-31 / ELAMIPRETIDE?

Start with identity.

A mitochondria-targeted peptide known as elamipretide; FDA accelerated approval is limited to a specific Barth syndrome indication.

Entity type
Synthetic peptide
Research category
Longevity
Names and aliases
SS-31 / Elamipretide · Elamipretide · Forzinity

HUMAN VS PRECLINICAL

What evidence exists for SS-31 / Elamipretide?

HUMAN EVIDENCE
3/5 · Narrow accelerated approval

Elamipretide received accelerated approval for a rare-disease indication based on a small clinical program; confirmatory work continues.

PRECLINICAL EVIDENCE
4/5 · Extensive mitochondrial research

A broad mitochondrial literature does not expand the approved indication beyond the label.

RESEARCH INTENT

What is SS-31 / Elamipretide being studied for?

Current source-backed research areas include the topics below. Inclusion means the area is being investigated; it does not establish a treatment benefit.

  • 01Barth syndrome
  • 02Mitochondrial cardiolipin
  • 03Muscle strength
  • 04Mitochondrial disease

U.S. REGULATORY STATUS

Is SS-31 / Elamipretide FDA approved?

FDA accelerated approval as Forzinity for Barth syndrome patients weighing at least 30 kg; other uses remain unapproved.

SPORT STATUS

Is SS-31 / Elamipretide prohibited in sport?

Not specifically named in the 2026 List; athletes should verify current status.

Anti-doping rules and product ingredients can change. Athletes should verify the current official list and the exact product before making a real decision.

EVIDENCE LIMITS

What can the current record not establish?

COMMON SEARCH INTENTS

Reviewed questions about SS-31 / Elamipretide.

Evidence

What is the evidence for SS-31 / Elamipretide?

SS-31 is no longer simply an unapproved research peptide: elamipretide now has one narrow accelerated-approval pathway, with confirmatory evidence still required.

2 sources Research

What is SS-31 / Elamipretide being studied for?

Current source-backed research areas include Barth syndrome, Mitochondrial cardiolipin, Muscle strength, Mitochondrial disease. These areas describe investigation, not established personal benefit.

2 sources FDA status

Is SS-31 / Elamipretide FDA approved?

Current U.S. status for SS-31 / Elamipretide: FDA accelerated approval as Forzinity for Barth syndrome patients weighing at least 30 kg; other uses remain unapproved.

2 sources Sport status

Is SS-31 / Elamipretide prohibited in sport?

Current sport-status snapshot for SS-31 / Elamipretide: Not specifically named in the 2026 List; athletes should verify current status.

2 sources Evidence limits

What are the main evidence limits for SS-31 / Elamipretide?

A rare-disease approval should not be generalized to longevity or performance claims.

2 sources

PRIMARY AND OFFICIAL SOURCES

Inspect the research behind this guide.